Michael S. Weiss - 18 Jun 2021 Form 4 Insider Report for TG THERAPEUTICS, INC. (TGTX)

Role: CEO and President, Director
Signature: /s/ Michael S. Weiss
Issuer symbol: TGTX
Transactions as of: 18 Jun 2021
Net transactions value: $0
Form type: 4
Filing time: 22 Jun 2021, 18:26:47 UTC
Previous filing: 11 Jun 2021
Next filing: 08 Jul 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TGTX	COMMON STOCK	Award	$0	+1,080,770	+8.3%	$0.000000	14,148,852	18 Jun 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the final annual grant of restricted stock pursuant to the Strategic Advisory Agreement with Caribe BioAdvisors, LLC, pursuant to which Mr. Weiss provided the services of Chairman of the Board and Executive Chairman. The restricted shares will vest on the date that the Company's Market Capitalization is $500 million greater than the Market Capitalization on the date of grant as measured within a five-year timeframe, but in no event before December 1, 2022.
F2	Included in Mr. Weiss' beneficial ownership are 4,909,355 shares of Common Stock issued to Opus Point Partners, LLC, of which Mr. Weiss is a principal and beneficially owns a 50% interest.

Content

Reflects the final annual grant of restricted stock pursuant to the Strategic Advisory Agreement with Caribe BioAdvisors, LLC, pursuant to which Mr. Weiss provided the services of Chairman of the Board and Executive Chairman. The restricted shares will vest on the date that the Company's Market Capitalization is $500 million greater than the Market Capitalization on the date of grant as measured within a five-year timeframe, but in no event before December 1, 2022.

Included in Mr. Weiss' beneficial ownership are 4,909,355 shares of Common Stock issued to Opus Point Partners, LLC, of which Mr. Weiss is a principal and beneficially owns a 50% interest.